Cbd Life Sciences Inc
CBD Life Sciences Inc. engages in the development and marketing a line of cannabidiol based organic products. Its cannabidiol based organic products include hemp drops, massage oils, recovery pain relief creams, anxiety and sleep solutions supplements, edibles, coffee, wine, skincare line, tablets, and a line of pet products. CBD Life Sciences Inc. formerly known as Optium Cyber Systems, Inc. and… Read more
Cbd Life Sciences Inc (CBDL) - Net Assets
Latest net assets as of March 2025: $436.05K USD
Based on the latest financial reports, Cbd Life Sciences Inc (CBDL) has net assets worth $436.05K USD as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($516.74K) and total liabilities ($80.70K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $436.05K |
| % of Total Assets | 84.38% |
| Annual Growth Rate | -1.48% |
| 5-Year Change | N/A |
| 10-Year Change | 376.61% |
| Growth Volatility | 266.18 |
Cbd Life Sciences Inc - Net Assets Trend (2011–2024)
This chart illustrates how Cbd Life Sciences Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cbd Life Sciences Inc (2011–2024)
The table below shows the annual net assets of Cbd Life Sciences Inc from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $392.61K | -0.50% |
| 2023-12-31 | $394.58K | +29.87% |
| 2022-12-31 | $303.82K | -77.21% |
| 2021-12-31 | $1.33 Million | +6640.54% |
| 2020-12-31 | $-20.38K | -101.98% |
| 2019-12-31 | $1.03 Million | +776.34% |
| 2018-12-31 | $117.68K | -95.04% |
| 2017-12-31 | $2.37 Million | +17839.87% |
| 2014-12-31 | $-13.37K | -116.23% |
| 2013-12-31 | $82.38K | -79.57% |
| 2012-12-31 | $403.30K | -15.41% |
| 2011-12-31 | $476.78K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cbd Life Sciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1468746100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.37 Million | 1112.08% |
| Other Components | $11.35 Million | 2889.80% |
| Total Equity | $392.61K | 100.00% |
Cbd Life Sciences Inc Competitors by Market Cap
The table below lists competitors of Cbd Life Sciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AngioSoma Inc
PINK:GSTC
|
$124.11K |
|
XRPR
BATS:XRPR
|
$124.20K |
|
Together Startup Network Ltd
TA:TGTR
|
$124.45K |
|
Konan Technology Inc.
KQ:402030
|
$124.46K |
|
J M AB
BE:JMM
|
$124.05K |
|
ATEA (MKL.SG)
STU:MKL
|
$123.93K |
|
Global Hemp Group Inc
PINK:GBHPF
|
$123.89K |
|
Inter Residence Fundo DE Investimento Imobiliario FII
SA:INRD11
|
$123.88K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cbd Life Sciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 394,584 to 392,613, a change of -1,971 (-0.5%).
- Net loss of 757,189 reduced equity.
- Other comprehensive income increased equity by 13,293.
- Other factors increased equity by 741,925.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-757.19K | -192.86% |
| Other Comprehensive Income | $13.29K | +3.39% |
| Other Changes | $741.92K | +188.97% |
| Total Change | $- | -0.50% |
Book Value vs Market Value Analysis
This analysis compares Cbd Life Sciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.37x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.00x to 2.37x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $8081.02 | $0.00 | x |
| 2012-12-31 | $6204.55 | $0.00 | x |
| 2013-12-31 | $514.85 | $0.00 | x |
| 2014-12-31 | $-7.34 | $0.00 | x |
| 2019-12-31 | $0.01 | $0.00 | x |
| 2020-12-31 | $0.00 | $0.00 | x |
| 2021-12-31 | $0.00 | $0.00 | x |
| 2022-12-31 | $0.00 | $0.00 | x |
| 2023-12-31 | $0.00 | $0.00 | x |
| 2024-12-31 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cbd Life Sciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -192.86%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -695.36%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 1.04x
- Recent ROE (-192.86%) is above the historical average (-340.54%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -11.06% | 0.00% | 0.00x | 0.93x | $-100.42K |
| 2012 | -38.76% | 0.00% | 0.00x | 1.07x | $-196.66K |
| 2013 | -445.68% | -236.02% | 0.23x | 8.05x | $-375.37K |
| 2014 | 0.00% | -635.35% | 0.19x | 0.00x | $-778.80K |
| 2017 | 53.45% | 49.00% | 0.96x | 1.13x | $1.02 Million |
| 2018 | -2781.74% | -401.49% | 2.20x | 3.15x | $-2.84 Million |
| 2019 | -83.49% | -1081.20% | 0.05x | 1.45x | $-964.13K |
| 2020 | 0.00% | -750.07% | 1.57x | 0.00x | $-1.69 Million |
| 2021 | -384.73% | -8654.24% | 0.04x | 1.02x | $-5.26 Million |
| 2022 | -181.72% | -536.57% | 0.34x | 1.00x | $-907.12K |
| 2023 | -19.91% | -47.01% | 0.40x | 1.06x | $-118.03K |
| 2024 | -192.86% | -695.36% | 0.27x | 1.04x | $-796.45K |
Industry Comparison
This section compares Cbd Life Sciences Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cbd Life Sciences Inc (CBDL) | $436.05K | -11.06% | 0.19x | $124.07K |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |